ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Poor Timing

September 24, 2007 | APPEARED IN VOLUME 85, ISSUE 39

AstraZeneca transferring production to China is a very poor move (C&EN, July 30, page 40). At a time when products coming from China are highly suspect for major quality defects, and when critical products such as pharmaceuticals are not being labeled with country of origin, most of us will be reluctant to trust AstraZeneca's pharmaceuticals. My family and I will avail ourselves of other companies' products whenever possible.

Peter R. Lantos
Erdenheim, Pa.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment